A detailed history of Ubs Asset Management Americas Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 755,112 shares of REGN stock, worth $591 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
755,112
Previous 847,682 10.92%
Holding current value
$591 Million
Previous $891 Million 10.9%
% of portfolio
0.21%
Previous 0.26%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $94.8 Million - $111 Million
-92,570 Reduced 10.92%
755,112 $794 Million
Q2 2024

Aug 13, 2024

BUY
$883.2 - $1071.19 $144 Million - $175 Million
163,118 Added 23.83%
847,682 $891 Million
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $16.4 Million - $18.1 Million
18,183 Added 2.73%
684,564 $659 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $22.5 Million - $25.6 Million
-29,006 Reduced 4.17%
666,381 $585 Million
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $20.2 Million - $24.7 Million
29,203 Added 4.38%
695,387 $572 Million
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $40 Million - $48.6 Million
58,828 Added 9.69%
666,184 $547 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $4.49 Million - $4.88 Million
6,362 Added 1.06%
607,356 $438 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $1.47 Million - $1.85 Million
-2,554 Reduced 0.42%
600,994 $414 Million
Q2 2022

Aug 12, 2022

BUY
$548.35 - $738.84 $15 Million - $20.2 Million
27,385 Added 4.75%
603,548 $357 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $18.9 Million - $22.2 Million
-31,755 Reduced 5.22%
576,163 $402 Million
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $45.5 Million - $56.2 Million
83,707 Added 15.97%
607,918 $384 Million
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $28.1 Million - $33.4 Million
-49,007 Reduced 8.55%
524,211 $317 Million
Q2 2021

Aug 16, 2021

SELL
$472.8 - $558.54 $21.3 Million - $25.2 Million
-45,128 Reduced 7.3%
573,218 $320 Million
Q1 2021

May 14, 2021

SELL
$446.73 - $548.2 $11.2 Million - $13.8 Million
-25,096 Reduced 3.9%
618,346 $293 Million
Q4 2020

Mar 01, 2021

BUY
$478.3 - $607.98 $24.5 Million - $31.2 Million
51,243 Added 8.65%
643,442 $311 Million
Q3 2020

Nov 13, 2020

BUY
$544.75 - $658.21 $49.1 Million - $59.3 Million
90,142 Added 17.95%
592,199 $332 Million
Q2 2020

Aug 14, 2020

BUY
$493.32 - $643.92 $82.9 Million - $108 Million
167,966 Added 50.28%
502,057 $313 Million
Q1 2020

May 15, 2020

BUY
$336.18 - $494.43 $955,087 - $1.4 Million
2,841 Added 0.86%
334,091 $163 Million
Q4 2019

Feb 14, 2020

SELL
$274.13 - $376.51 $731,104 - $1 Million
-2,667 Reduced 0.8%
331,250 $124 Million
Q3 2019

Nov 14, 2019

SELL
$273.46 - $318.39 $20.5 Million - $23.8 Million
-74,874 Reduced 18.32%
333,917 $92.6 Million
Q2 2019

Aug 15, 2019

SELL
$299.6 - $414.82 $267,243 - $370,019
-892 Reduced 0.22%
408,791 $0
Q1 2019

May 14, 2019

BUY
$372.08 - $439.57 $31.7 Million - $37.5 Million
85,327 Added 26.31%
409,683 $0
Q4 2018

Feb 13, 2019

BUY
$335.82 - $403.04 $2.04 Million - $2.45 Million
6,070 Added 1.91%
324,356 $121 Million
Q3 2018

Nov 14, 2018

SELL
$351.14 - $408.51 $7.79 Million - $9.06 Million
-22,172 Reduced 6.51%
318,286 $0
Q2 2018

Aug 14, 2018

SELL
$284.6 - $344.99 $180,436 - $218,723
-634 Reduced 0.19%
340,458 $0
Q1 2018

May 14, 2018

SELL
$315.82 - $393.78 $67.1 Million - $83.6 Million
-212,409 Reduced 38.38%
341,092 $0
Q4 2017

Feb 09, 2018

BUY
$358.63 - $469.95 $95.9 Million - $126 Million
267,442 Added 93.49%
553,501 $0
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $123 Million - $144 Million
286,059
286,059 $0

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $83.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.